Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

ItalyBack to Italy

Clinical trials in Monserrato – page 11

178 clinical trials in Monserrato, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Monserrato at a glance
178
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

178 trials in Monserrato

Open in trial search

Plasma cell myeloma

Not recruiting

Study on Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Eligible for Autologous Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Universita' Degli Studi Di Torino

Acute myeloid leukaemia

Not recruiting

Study on Pentaglobin for Treating Fever in Acute Leukemia or Stem Cell Transplant Patients with Resistant Bacteria

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Immunoglobulin G
  • Sponsor:Gruppo Italiano Per Il Trapianto Di Midollo Osseo Cellule Staminali Emopoietiche E Terapia Cellulare

Colorectal cancer metastatic

Not recruiting

Study on Cetuximab-Based Treatment for Metastatic Colorectal Cancer in Patients with RAS/BRAF Wild Type Tumors

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gruppo Oncologico Dell'Italia Meridionale

Diffuse large B-cell lymphoma

Not recruiting

Study on the Effectiveness and Safety of Ibrutinib with Rituximab-CHOP for Untreated Patients with Diffuse Large B-cell Lymphoma at High Risk

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cyclophosphamide
  • Sponsor:Fondazione Italiana Linfomi Ets

Primary progressive multiple sclerosis

Not recruiting

Study on Tolebrutinib for Patients with Primary Progressive Multiple Sclerosis

Investigational
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Tolebrutinib
  • Sponsor:Genzyme Corp.

Colorectal cancer metastatic+1

Not recruiting

Study of Encorafenib, Cetuximab, and Pembrolizumab for Patients with Untreated BRAF V600E-Mutant Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cetuximab
  • Sponsor:Pfizer Inc.

Thalassaemia

Not recruiting

Study on the Effectiveness and Safety of Mitapivat for Patients with Non-Transfusion-Dependent Alpha or Beta Thalassemia

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Study Comparing Savolitinib and Osimertinib with Chemotherapy for Advanced Non-Small Cell Lung Cancer in Patients with EGFR Mutation and MET Overexpression

Not recruiting
Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Astrazeneca AB

Thalassaemia

Not recruiting

Study on the Effects of Mitapivat for Patients with Transfusion-Dependent Alpha or Beta Thalassemia

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Mitapivat
  • Sponsor:Agios Pharmaceuticals Inc.

Plasma cell myeloma

Not recruiting

Study Comparing Bortezomib, Melphalan, Prednisone, Lenalidomide, and Daratumumab for Multiple Myeloma in Patients Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:65+ years
  • Substances:Bortezomib
  • Sponsor:Universita' Degli Studi Di Torino

Plasma cell myeloma

Not recruiting

Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone with Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma Patients Ineligible for Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Fondazione European Myeloma Network Italy O.N.L.U.S.

Autism spectrum disorder

Not recruiting

Study on the Long-Term Safety of Pimavanserin for Treating Irritability in Children and Adolescents with Autism Spectrum Disorder

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Pimavanserin Tartrate
  • Sponsor:Acadia Pharmaceuticals Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Monserrato

What the registry says about research in the country

01 Oncology Research

Groundbreaking clinical trials focusing on colorectal cancer, breast cancer, and hepatocellular carcinoma. Studies evaluate novel targeted therapies and combination treatments for both early-stage and metastatic diseases.

  • KRAS G12C mutation treatments
  • Hormone receptor-positive breast cancer
  • Advanced colorectal adenocarcinoma

Multiple trials exploring innovative approaches to cancer treatment, including biomarker-driven therapies and immunotherapy combinations.

02 Autoimmune Conditions

Innovative research in rheumatoid arthritis and ulcerative colitis, investigating new biological therapies and treatment combinations to improve patient outcomes.

  • Molecular profiling in RA
  • Novel UC treatments
  • Systemic sclerosis studies

Focus on developing precision medicine approaches and understanding biomarker-based treatment responses.

03 Respiratory Medicine

Clinical trials examining new treatments for asthma and interstitial lung disease, with emphasis on innovative delivery systems and targeted therapies.

  • Advanced asthma treatments
  • Bronchial disease management
  • Lung volume assessments

Studies evaluate both established and novel therapeutic approaches for respiratory conditions.

Back to ItalyAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.